Global Plasma Protein Therapeutics Market Segments 2024, Forecast To 2033

5 Mar, 2024

The plasma protein therapeutics market has experienced strong growth, escalating from $29.66 billion in 2023 to $32.22 billion in 2024, reflecting an 8.6% CAGR. Historic growth is attributed to the increasing prevalence of rare diseases, a growing aging population, the global blood plasma supply, a rise in hemophilia cases, improvements in diagnosis, and a supportive regulatory environment. The market is poised for strong growth, projecting a size of $43.85 billion in 2028 with an 8.0% CAGR. The anticipated growth is fueled by gene therapy advancements, increasing healthcare expenditure, expanded indications, precision medicine approaches, and patient access programs, with major trends including technological innovations, telemedicine adoption, technological advancements in plasma fractionation, the development of next-generation therapies, the adoption of recombinant therapies, and personalized medicine approaches.

Global Plasma Protein Therapeutics Market Key Driver

Plasma protein therapeutics market growth is fueled by the increasing prevalence of autoimmune disorders. Autoimmune diseases affect 4% of the global population, necessitating therapeutic plasma exchange. The demand for plasma protein therapeutics rises as autoimmune disorders become more prevalent.

Get A Free Sample Of The Global Plasma Protein Therapeutics Market Report

Global Plasma Protein Therapeutics Market Segments

The plasma protein therapeutics market covered in this report is segmented –
1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions. North America was the largest region in the plasma protein therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Major Plasma Protein Therapeutics Industry Players

CSL Behring LLC; Grifols SA; China Biologic Products Holdings Inc.; Takeda Pharmaceutical Company Limited; Baxter International Inc.; Kedrion SpA; Shire plc; LFB SA; Emergent BioSolutions Inc.; Reliance Life Sciences Private Limited; ADMA Biologics Inc.; Prothya Biosolutions BV; Bio Products Laboratory Ltd.; MP Biomedicals LLC; Biotest AG; Taibang Biological Group Co Ltd; Arthrex Inc.; Johnson and Johnson; Abeona Therapeutics Inc.; Octapharma Plasma Inc.; Bayer AG; Bioverativ Inc.; Grifols Biologicals Inc.; Baxalta US Inc.; New York Blood Center; Green Cross Corporation; China National Biotec Group Company Limited; Kamada Ltd.; Australian Red Cross Lifeblood

Get The Full Global Plasma Protein Therapeutics Market Report

AIOps Plasma Protein Therapeutics Market Overview

Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives.

Plasma Protein Therapeutics Global Market Report 2023 provides data on the global plasma protein therapeutics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The plasma protein therapeutics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.